Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 15/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19125220 | 0.91 | ADORA3 (0.65) | ADORA3ADORA2A | |
| SCHEMBL19124229 | 0.79 | ADORA3 (1.00) | ADORA3ADORA2A | |
| SCHEMBL19124156 | 0.78 | ADORA3 (0.69) | ADORA3ADORA2A | |
| SCHEMBL19124330 | 0.78 | ADORA3 (0.66) | ADORA3ADORA2A | |
| SCHEMBL19124400 | 0.76 | ADORA3 (0.62) | ADORA3ADORA2A | |
| SCHEMBL19124986 | 0.74 | ADORA3 (0.51) | ADORA3ADORA2A | |
| SCHEMBL19124437 | 0.74 | ADORA2A (0.62) | ADORA3ADORA2A | |
| SCHEMBL19124375 | 0.74 | ADORA3 (0.67) | ADORA3ADORA2A | |
| SCHEMBL19125427 | 0.74 | ADORA3 (0.68) | ADORA3ADORA2A | |
| SCHEMBL19124207 | 0.74 | ADORA3 (0.68) | ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC. (KR) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA2A 1/4885FLT3 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.